

S1 Table. Demographic characteristics and vaccine status of cohort individuals aged 65 to 79 years old, Portugal, March–August 2021 (n = 1,414,909).

| | Vaxzevria 499,770 | Janssen 40,484 | mRNA 760,176 | Unvaccinated 114,479 |
|---|----------------------|--------------------|--------------------|-------------------------|
| Age (years), median (IQR) | 71.0 (68.0 - 75.0) | 69.0 (67.0 - 72.0) | 71.0 (68.0 - 75.0) | 71.0 (68.0 - 75.0) |
| Age group, (%) | | | | |
| 65-69 | 178,573 (35.7%) | 21,890 (54.1%) | 297,449 (39.1%) | 43,262 (37.8%) |
| 70-74 | 194,191 (38.9%) | 12,776 (31.6%) | 257,681 (33.9%) | 39,124 (34.2%) |
| 75-79 | 127,006 (25.4%) | 5,818 (14.4%) | 205,046 (27.0%) | 32,093 (28.0%) |
| Sex Male, n (%) | 221,369 (44.3%) | 18,407 (45.5%) | 332,106 (43.7%) | 51,302 (44.8%) |
| Region, n (%) | | | | |
| Alentejo | 27,817 (5.6%) | 2,592 (6.4%) | 35,331 (4.6%) | 4,538 (4.0%) |
| Algarve | 27,567 (5.5%) | 6,318 (15.6%) | 29,480 (3.9%) | 12,502 (10.9%) |
| Centro | 97,820 (19.6%) | 10,582 (26.1%) | 133,943 (17.6%) | 19,034 (16.6%) |
| LVT | 212,153 (42.5%) | 11,646 (28.8%) | 234,669 (30.9%) | 41,354 (36.1%) |
| Norte | 132,245 (26.5%) | 8,864 (21.9%) | 322,412 (42.4%) | 25,612 (22.4%) |
| Missing | 2,168 (0.4%) | 482 (1.2%) | 4,341 (0.6%) | 11,439 (10.0%) |
| EDI Quintile, n (%) | | | | |
| Q1 (least deprived) | 66,389 (13.3%) | 10,092 (24.9%) | 118,691 (15.6%) | 13,898 (12.1%) |
| Q2 | 78,578 (15.7%) | 3,584 (8.9%) | 112,593 (14.8%) | 13,854 (12.1%) |
| Q3 | 74,384 (14.9%) | 3,438 (8.5%) | 111,310 (14.6%) | 13,251 (11.6%) |
| Q4 | 137,234 (27.5%) | 10,097 (24.9%) | 221,903 (29.2%) | 27,751 (24.2%) |
| Q5 (most deprived) | 141,017 (28.2%) | 12,791 (31.6%) | 191,338 (25.2%) | 34,286 (29.9%) |
| Missing | 2,168 (0.4%) | 482 (1.2%) | 4,341 (0.6%) | 11,439 (10.0%) |
| Number of chronic diseases, n (%) | | | | |
| 0 | 114,499 (22.9%) | 11,877 (29.3%) | 172,206 (22.7%) | 56,005 (48.9%) |
| 1 | 130,811 (26.2%) | 10,636 (26.3%) | 199,291 (26.2%) | 24,891 (21.7%) |
| 2 | 123,914 (24.8%) | 9,162 (22.6%) | 187,622 (24.7%) | 17,238 (15.1%) |
| 3 | 79,620 (15.9%) | 5,507 (13.6%) | 121,101 (15.9%) | 9,755 (8.5%) |
| 4 | 34,814 (7.0%) | 2,274 (5.6%) | 54,174 (7.1%) | 4,406 (3.8%) |
| 5+ | 16,112 (3.2%) | 1,028 (2.5%) | 25,782 (3.4%) | 2,184 (1.9%) |
| Number of SARS-CoV-2 tests in 2021, n (%) | | | | |
| 0 | 390,166 (78.1%) | 30,999 (76.6%) | 597,080 (78.5%) | 88,703 (77.5%) |
| 1 | 66,129 (13.2%) | 5,226 (12.9%) | 95,874 (12.6%) | 14,323 (12.5%) |
| 2 | 23,741 (4.8%) | 1,865 (4.6%) | 34,980 (4.6%) | 4,943 (4.3%) |
| 3 | 8,557 (1.7%) | 798 (2.0%) | 12,593 (1.7%) | 2,021 (1.8%) |
| 4-9 | 9,835 (2.0%) | 1,277 (3.2%) | 16,586 (2.2%) | 3,514 (3.1%) |
| 10+ | 1,342 (0.3%) | 319 (0.8%) | 3,063 (0.4%) | 975 (0.9%) |
| Any other vaccine, n (%)† | 325,333 (65.1%) | 18,503 (45.7%) | 497,594 (65.5%) | 21,684 (18.9%) |

† received at least one of the following vaccines since 2016, influenza, pn23, pcv 7, 10 or 13